The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.
13h
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COPD) showed that tozorakimab reduced the annualized rate of ...
Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Measures including Disease Severity, Itch, and ...
Chronic liver disease affects 1.5 billion people globally, of whom 18.3% are of Indian origin, indicating a significant liver ...
GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.
AstraZeneca jumps 4% after COPD drug wins Phase 3 trials. Tozorakimab success seen as rare win in tough COPD drug race.
AstraZeneca PLC on Friday reported positive phase-three trial results for its chronic obstructive pulmonary disease treatment ...
Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary ...
Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics ...
AstraZeneca PLC (ST:AZN) shares rose 2.8% Friday after the company announced that tozorakimab met its primary endpoint in two ...
When a virus enters the lungs, the immune system has to react fast. The lung maintains its own community of immune cells ...
ImmunityBio has received approval from the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results